Autolus Therapeutics AUTL 深 滬
已收盤 05-15 16:00:00 美东时间
1.63
+0.040
+2.52%
華盛通- 最 高1.63
- 今 開1.58
- 成交量 148.28万股
- 最 低 1.53
- 昨 收 1.59
- 總市值 4.34亿
- 52周最高 2.70
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 1.175
- 委 比 -61.40%
- 總股本 2.66亿
- 歷史最高 53.24
- 量 比 0.86
- 振 幅 6.29%
- 歷史最低 1.105
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Autolus Therapeutics shares are trading lower. The company reported its Q1 financial results.
Autolus Therapeutics shares are trading lower. The company reported its Q1 fina...
05-14 23:25
Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Autolus Therapeutics (NASDAQ:AUTL) released first-quarter financial results and...
05-14 21:42
Autolus Therapeutics Sees FY2026 Sales $120.000M-$135.000M vs $130.062M Est
Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.062 million analyst estimate.
05-14 20:58
Autolus Therapeutics Q1 EPS $(0.27), Inline, Sales $26.218M Beat $26.160M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 3.85 percent decrease over losses of $(0.26) per share from the same period last year.
05-14 19:12
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported $26.2 million in net product revenue for Q1 2026, driven by strong launches in the US and UK for AUCATZYL® (obe-cel). The company achieved positive gross margin for its ALL business and is implementing cost reduction initiatives to improve profitability. Obe-cel's clinical development is progressing across multiple indications, including lupus nephritis, pediatric ALL, and progressive MS. Autolus expects full-year 20...
05-14 11:00
Autolus Therapeutics Plans To Cut Workforce By ~13% As Part Of Initiative To Enhance Operational Efficiency, Lower Operating Expenses
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced a strategic
04-30 04:24
Autolus Highlights ALL Opportunity and AUCATZYL CAR-T Platform
Autolus Therapeutics ( ($AUTL) ) just unveiled an update. On April 8, 2026, Aut...
04-09 05:13
